GentiBio partners with Bristol Myers as cell therapy for immune disease gains momentum
Bio Pharma Dive
AUGUST 10, 2022
The deal, worth as much as $2 billion, is the latest sign of industry interest in treatments that harness regulatory T cells, an approach behind several recent biotech startups.
Let's personalize your content